Nitric Oxide Modulation as a Therapeutic Strategy in Heart Failure

Heart Failure Clinics

Volumn 8, Issue 2, 2012, Pages 255-272

  Taylor, Anne L ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Heart failure; Nitric oxide; Oxidant stress

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CINACIGUAT; CYCLIC GMP; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED RELAXING FACTOR; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPID; LOW DENSITY LIPOPROTEIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PEROXYNITRITE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SILDENAFIL; SPIRONOLACTONE;

BETA ADRENERGIC STIMULATION; CARDIOVASCULAR DISEASE; CELL COMPARTMENTALIZATION; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME SYNTHESIS; GENE EXPRESSION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART RATE; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTENSION; LUNG WEDGE PRESSURE; MEAN ARTERIAL PRESSURE; MOLECULARLY TARGETED THERAPY; NERVE CELL; NITROSYLATION; OXIDATION REDUCTION STATE; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; THROMBOGENICITY; TREATMENT DURATION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

BIOLOGICAL AVAILABILITY; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; GUANYLATE CYCLASE; HEART FAILURE; HUMANS; NITRIC OXIDE; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SIGNAL TRANSDUCTION; SULFONES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84858113250     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.11.002     Document Type: Review

References (124)

1. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288(5879):373-376.
2. Moncada S., Herman A.G., Vanhoutte P. Endothelium-derived relaxing factor is identified as nitric oxide. Trends Pharmacol Sci 1987, 8(10):365-368.
3. Ignarro L.J. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep 1999, 19(2):51-71.
4. Loscalzo J., Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995, 38(2):87-104.
5. Pacher P., Beckman J.S., Liaudet L., et al. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87(1):315-424.
6. Massion P.B., Feron O., Dessy C., et al. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003, 93(5):388-398.
7. Moens A.L., Yang R., Watts V.L., et al. Beta 3-adrenor eceptor regulation of nitric oxide in the cardiovascular system. J Mol Cell Cardiol 2010, 48(6):1088-1095.
8. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43(2):109-142.
9. Michel T. NO way to relax: the complexities of coupling nitric oxide synthase pathways in the heart. Circulation 2010, 121(4):519-528.
10. Schultz H.D. Nitric oxide regulation of autonomic function in heart failure. Curr Heart Fail Rep 2009, 6(2):71-80.
11. Prabhu S.D. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res 2004, 94(9):1155-1157.
12. Barouch L.A., Harrison R.W., Skaf M.W., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase. Nature 2002, 416(6878):337-339.
13. Hare J.M. Spatial confinement of isoforms of cardiac nitric-oxide synthase: unraveling the complexities of nitric oxide's cardiobiology. Lancet 2004, 363(9418):1338-1339.
14. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87:840-844.
15. Damy T., Ratajczak P., Robidel E., et al. Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats. FASEB J 2003, 17(13):1934-1936.
16. Damy T., Ratajczak P., Shah A.M., et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004, 363(9418):1365-1367.
17. Drexler H., Hayoz D., Munzel T., et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992, 69(19):1596-1601.
18. Heusch G., Boengler K., Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008, 118(19):1915-1919.
19. Mohri M., Egashira K., Tagawa T., et al. Basal release of nitric oxide is decreased in the coronary circulation in patients with heart failure. Hypertension 1997, 30(1Pt1):50-56.
20. Recchia F.A., McConnell P.I., Bernstein R.D., et al. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998, 83(10):969-979.
21. Ruiz-Hurtado G., Delgado C. Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors. J Hypertens 2010, 28(Suppl 1):S56-S61.
22. Saraiva R.M., Hare J.M. Nitric oxide signaling in the cardiovascular system: implications for heart failure. Curr Opin Cardiol 2006, 21(3):221-228.
23. Umar S., van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem 2010, 333(1-2):191-201.
24. Winlaw D., Smythe G., Keogh A.M., et al. Increased nitric oxide production in heart failure. Lancet 1994, 344:373-374.
25. Zimmet J.M., Hare J.M. Nitroso-redox interactions in the cardiovascular system. Circulation 2006, 114(14):1531-1544.
26. Gonzalez D.R., Treuer A., Sun Q.A., et al. S-Nitrosylation of cardiac ion channels. J Cardiovasc Pharmacol 2009, 54(3):188-195.
27. Hess D.T., Foster M.W., Stamler J.S. Assays for S-nitrosothiols and S-nitrosylated proteins and mechanistic insights into cardioprotection. Circulation 2009, 120(3):190-193.
28. Foster M.W., Hess D.T., Stamler J.S. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009, 15(9):391-404.
29. Lima B., Forrester M.T., Hess D.T., et al. S-nitrosylation in cardiovascular signaling. Circ Res 2010, 106:633.
30. Gryglewski R., Palmer R.M., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456.
31. Guzik T.J., West N.E., Black E., et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000, 86(9):E85-E90.
32. López Farré A., Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension 2001, 38(6):1400-1405.
33. Nediani C., Raimondi L., Borchi E., et al. Nitric oxide/reactive oxygen species generation and nitroso/redox imbalance in heart failure: from molecular mechanisms to therapeutic implications. Antioxid Redox Signal 2011, 14(2):289-331.
34. Heymes C., Bendall J.K., Ratajczak P., et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003, 41(12):2164-2171.
35. Keith M., Geranmayegan A., Sole M.J., et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998, 31(6):1352-1356.
36. Kubo S.H., Rector T.S., Bank A.J., et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991, 84(4):1589-1596.
37. Münzel T., Harrison D.G. Increased superoxide in heart failure a biochemical baroreflex gone awry. Circulation 1999, 100:216-218.
38. Sharma R., Davidoff M.N. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 2002, 8(3):165-172.
39. Shizukuda Y., Buttrick P.M. Oxygen free radicals and heart failure: new insight into an old question. Am J Physiol Lung Cell Mol Physiol 2002, 283(2):L237-L238.
40. Smith C.J., Sun D., Hoegler C., et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 1996, 78(1):58-64.
41. Takimoto E., Kass D.A. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007, 49(2):241-248.
42. Trachtenberg B.H., Hare J.M. Biomarkers of oxidative stress in heart failure. Heart Fail Clin 2009, 5(4):561-577.
43. Wang J., Seyedi N., Xu X.B., et al. Defective endothelium mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol 1994, 266:H670-H680.
44. Diaz-Velez C., Garcia-Castineiras S., Mendoza-Ramos E., et al. Increased malondialdehyde peripheral blood of patients with congestive heart failure. Am Heart J 1996, 131(1):146-152.
45. Belch J., Bridges A.B., Scott N., et al. Oxygen free radicals and congestive heart failure. Br Heart J 1991, 65:245-248.
46. Janssens S., Pokreisz P., Schoonjans L., et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004, 94(9):1256-1262.
47. Scherrer-Crosbie M., Ullrich R., Bloch K.D., et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001, 104(11):1286-1291.
48. Takimoto E., Champion H.C., Li M., et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005, 115(5):1221-1231.
49. Rohde D., Ritterhoff J., Voelkers M., et al. S100A1: a multifaceted therapeutic target in cardiovascular disease. J Cardiovasc Transl Res 2010, 3(5):525-537.
50. Fraccarollo D., Widder J.D., Galuppo P., et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008, 118(8):818-827.
51. Ignarro L., Napoli C., Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide. Circ Res 2002, 90:21-28.
52. Chen Z., Zhang J., Stamler J.S. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002, 99(12):8306-8311.
53. Ignarro L.J., Lippton H., Edwards J.C., et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981, 218(3):739-749.
54. Daiber A., Wenzel P., Oelze M., et al. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 2008, 97(1):12-20.
55. Ignarro L.J. After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc Natl Acad Sci U S A 2002, 99(12):7816-7817.
56. den Uil C.A., Caliskan K., Lagrand W.K., et al. Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure. Intensive Care Med 2009, 35(11):1893-1899.
57. Sydow K., Daiber A., Oelze M., et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004, 113(3):482-489.
58. Parker J.D. Nitrate tolerance, oxidative stress, and mitochondrial function: another worrisome chapter on the effects of organic nitrates. J Clin Invest 2004, 113(3):352-354.
59. Gori T., Dragoni S., Di Stolfo G., et al. Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study. Am J Physiol Heart Circ Physiol 2010, 298(2):H340-H345.
60. Thomas G.R., DiFabio J.M., Gori T., et al. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 2007, 49(12):1289-1295.
61. Dragoni S., Gori T., Lisi M., et al. Pentaerythrityltetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol 2007, 27(9):1955-1959.
62. Daiber A., Wenzel P., Oelze M., et al. Mitochondrial aldehyde dehydrogenase (ALDH-2)-maker of and marker for nitrate tolerance in response to nitroglycerin treatment. Chem Biol Interact 2009, 178(1-3):40-47.
63. Elkayam U. Nitrates in the treatment of congestive heart failure. Am J Cardiol 1996, 77:41C-51C.
64. Elkayam U., Bitar F. Effects of nitrates and hydralazine in heart failure: clinical evidence before the African American Heart Failure Trial. Am J Cardiol 2005, 96(7B):37i-43i.
65. Packer M., Lee W.H., Kessler P.D., et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987, 317(13):799-804.
66. Unger P., Berkenboom G., Fontaine J. Interaction between hydralazine and nitrosovasodilators in vascular smooth muscle. J Cardiovasc Pharmacol 1993, 21:478-483.
67. Daiber A., Oelze M., Coldewey M., et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 2005, 338(4):1865-1874.
68. Münzel T., Kurz S., Rajagopalan S., et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996, 98(6):1465.
69. Leiro J.M., álvarez E., Arranz J.A., et al. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int Immunopharmacol 2004, 4(2):163-177.
70. Bauer J.A., Fung H.L. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991, 84(1):35-39.
71. Gogia H., Mehra A., Parikh S., et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995, 26(7):1575-1580.
72. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986, 314:1547-1552.
73. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
74. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure-complete report 2003, NIH Publication No. 03-5231, National Heart, Lung, and Blood Institute, Washington, DC.
75. Exner D., Dries D.L., Domanski M.J., et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344(18):1351-1357.
76. Carson P., Ziesche S., Johnson G., et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999, 5(3):178-187.
77. Franciosa J.A., Taylor A.L., Cohn J.N., et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002, 8:128-135.
78. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351(20):2049-2057.
79. Taylor A.L., Lindenfeld J., Ziesche S., et al. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol 2006, 48:2263-2267.
80. Ghali J.K., Tam S.W., Sabolinski M.L., et al. Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African American Heart Failure Trial. J Card Fail 2008, 4:718-723.
81. Farguharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101(6):594-597.
82. Cohn J.N., Tam S.W., Anand I.S., et al. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail 2007, 13(5):331-339.
83. Mitchell J., Tam W., Trivedi K., et al. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT). Am Heart J 2011, 162(1):154-159.
84. Anand I., Tam S.W., Rector T., et al. Influence of blood pressure on the effectiveness of isosorbide dinitrate and hydralazine combination in the African-American Heart Failure Trial. J Am Coll Cardiol 2007, 49:32-39.
85. Cohn J.N., Ziesche S., Smith R., et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997, 96:856-863.
86. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996, 335:1107-1114.
87. Boerrigter G., Burnett J.C. Soluble guanylate cyclase: not a dull enzyme. Circulation 2009, 119(21):2752-2754.
88. Ignarro L.J., Adams J.B., Horwitz P.M., et al. Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms. J Biol Chem 1986, 261(11):4997-5002.
89. Priviero F.B., Webb R.C. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol 2010, 56(3):229-233.
90. Ritchie R.H., Irvine J.C., Rosenkranz A.C., et al. Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. Pharmacol Ther 2009, 124(3):279-300.
91. Stasch J.P., Pacher P., Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011, 123(20):2263-2273.
92. Ko F.N., Wu C.C., Kuo S.C., et al. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84(12):4226-4233.
93. Stasch J.P., Becker E.M., Alonso-Alija C., et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001, 410(6825):212-215.
94. Boerrigter G., Costello-Boerrigter L.C., Cataliotti A., et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003, 107(5):686-689.
95. Boerrigter G., Costello-Boerrigter L.C., Cataliotti A., et al. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007, 49(5):1128-1133.
96. Stasch J.P., Schmidt P., Alonso-Alija C., et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002, 136(5):773-783.
97. Mitrovic V., Hernandez A.F., Meyer M., et al. Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev 2009, 14(4):309-319.
98. Boerrigter G., Burnett J.C. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev 2007, 25(1):30-45.
99. Hingorany S., Frishman W.H. Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure. Cardiol Rev 2011, 19(1):23-29.
100. Korkmaz S., Radovits T., Barnucz E., et al. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation 2009, 120(8):677-686.
101. Evgenov O.V., Pacher P., Schmidt P.M., et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006, 5(9):755-768.
102. Ghofrani H.A., Voswinckel R., Gall H. Riociguat for pulmonary hypertension. Future Cardiol 2010, 6(2):155-166.
103. Belik J. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Curr Opin Investig Drugs 2009, 10(9):971-979.
104. Schäfer A., Fraccarollo D., Werner L., et al. Guanylyl cyclase activator cinaciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res 2010, 62(5):432-438.
105. Lapp H., Mitrovic V., Franz N., et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009, 119(21):2781-2788.
106. Mueck W., Frey R. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure. Clin Pharmacokinet 2010, 49(2):119-129.
107. Grimminger F., Weimann G., Frey R., et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009, 33(4):785-792.
108. Kass D.A., Takimoto E., Nagayama T., et al. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 2007, 75(2):303-314.
109. Kass D.A., Champion H.C., Beavo J.A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007, 101(11):1084-1095.
110. Fischmeister R., Castro L.R., Abi-Gerges A., et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006, 99(8):816-828.
111. Galiè N., Ghofrani H.A., Torbicki A., et al. Sildenafil use in pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353(20):2148-2157.
112. Galiè N., Brundage B.H., Ghofrani H.A., et al. Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119(22):2894-2903.
113. Lu Z., Xu X., Hu X., et al. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 2010, 121(13):1474-1483.
114. Nagendran J., Archer S.L., Soliman D., et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116(3):238-248.
115. Pokreisz P., Vandenwijngaert S., Bito V., et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009, 119(3):408-416.
116. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11(2):214-222.
117. Nagayama T., Hsu S., Zhang M., et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 2009, 53(2):207-215.
118. Lewis G.D., Lachmann J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115(1):59-66.
119. Lindman B.R., Chakinala M.M. Modulating the nitric oxide-cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension. Int J Clin Pract Suppl 2010, 64(168):15-22.
120. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007, 116(14):1555-1562.
121. Lewis G.D., Semigran M.J. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr Heart Fail Rep 2004, 1(4):183-189.
122. Behling A., Rohde L.E., Colombo F.C., et al. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008, 14(3):189-197.
123. Guazzi M., Samaja M., Arena R., et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007, 50(22):2136-2144.
124. Guazzi M., Vicenzi M., Arena R., et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011, 4(1):8-17.